Cytokinetics
CYTK
$76.76
-5.67%
Cytokinetics Inc. is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors for debilitating diseases where muscle performance is compromised, including heart failure, amyotrophic lateral sclerosis, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's lead product, MYQORZO (omecamtiv mecarbil), is an allosteric activator of cardiac myosin, positioning Cytokinetics as a pioneer in muscle biology with a differentiated mechanism of action. Currently, the stock is in the spotlight due to the commercial launch of MYQORZO, which is driving revenue growth, and the market is closely watching the drug's uptake, pipeline progress, and the company's path to profitability. Investor sentiment is buoyed by strong analyst support and recent price momentum, though the company remains unprofitable, with ongoing R&D investments and commercialization costs shaping the narrative.…
CYTK
Cytokinetics
$76.76
Investment Opinion: Should I buy CYTK Today?
Rating: Buy. The consensus is a Strong Buy with an average target of $107.80, implying 32.5% upside. The thesis is that MYQORZO's launch will drive exponential revenue growth, leading to profitability and justifying the premium valuation. Supporting evidence includes 11.26% YoY revenue growth in Q1 2026, a high gross margin of 87.6%, analyst revenue estimates of $2.32B for next fiscal year, and a strong balance sheet with a current ratio of 4.53. The stock is trading at 86.6x sales, which is rich but may be justified if the company achieves its growth targets.
Sign up to view all
CYTK 12-Month Price Forecast
The AI model leans bullish given the strong analyst support and revenue growth potential, but confidence is medium due to the extreme valuation and persistent losses. The key factor is whether MYQORZO can deliver on its commercial promise. If revenue growth accelerates and the company moves toward profitability, the stock could re-rate higher. Conversely, any miss could trigger a sharp correction. The model would upgrade to high confidence if revenue growth exceeds 50% YoY and cash burn decreases, and downgrade to bearish if revenue stagnates or pipeline fails.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cytokinetics's 12-month outlook, with a consensus price target around $108.85 and implied upside of +41.8% versus the current price.
Average Target
$108.85
0 analysts
Implied Upside
+41.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$85 - $146
Analyst target range
Cytokinetics is covered by 20 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.5 on a 1-5 scale, where 1 is Strong Buy). The average price target is $107.80, implying a 32.5% upside from the current price of $81.37. The distribution of ratings is overwhelmingly bullish, with no sell ratings, and recent actions include upgrades from UBS (Neutral to Buy) and reaffirmations of Overweight/Buy from major firms like RBC, Morgan Stanley, and JP Morgan. The target price range spans from $83.00 (low) to $146.00 (high), with the low target slightly above the current price, indicating that even the most bearish analyst sees limited downside. The wide spread between low and high targets (76% difference) reflects high uncertainty about the commercial success of MYQORZO and pipeline outcomes, but the overall sentiment is strongly positive, with analysts expecting significant revenue growth (estimated revenue of $2.32 billion for the next fiscal year) and a potential turnaround to profitability (estimated EPS of $4.17).
Bulls vs Bears: CYTK Investment Factors
Cytokinetics presents a classic high-risk, high-reward biotech opportunity. The bull case rests on strong analyst support, a promising commercial launch, and a deep pipeline, while the bear case centers on extreme valuation, persistent losses, and revenue concentration. Currently, the bull side has stronger evidence given the unanimous Strong Buy rating and the potential for explosive revenue growth, but the stock's valuation leaves little room for error. The most critical tension is whether MYQORZO's commercial uptake can justify the 86x sales multiple; if revenue fails to meet the aggressive analyst estimates, the stock could face severe de-rating.
Bullish
- Strong Buy consensus with 32.5% upside: 20 analysts rate CYTK a Strong Buy (mean 1.5), with an average target of $107.80, implying 32.5% upside from $81.37. Even the lowest target of $83.00 is above the current price, signaling limited downside per sell-side.
- Revenue growth accelerating post-launch: Q1 2026 revenue grew 11.26% YoY to $19.36M, driven by MYQORZO launch. Analysts project revenue to surge to $2.32B next fiscal year, a massive jump from current run-rate, reflecting expected commercial ramp.
- High gross margin of 87.6%: Gross margin for Q1 2026 was 87.64%, indicating strong pricing power for MYQORZO. This high margin provides a solid foundation for future profitability as revenue scales.
- Strong price momentum and relative strength: Stock up 131.56% over the past year vs. S&P 500's 21.46%, with relative strength of 110.1% over 1Y. Trading near 52-week high ($88.31) at $81.37, reflecting robust investor confidence.
Bearish
- Extreme valuation at 86.6x sales: PS ratio of 86.62x is far above biotech industry average of 5-10x for commercial-stage companies. EV/Sales at 98.63x implies the market is pricing in flawless execution and massive future revenue.
- Persistent losses and negative cash flow: Q1 2026 net loss of $206M and operating margin of -948.7%. TTM free cash flow is -$549M, indicating significant cash burn that may require dilution or debt.
- Revenue volatility and dependence on one product: Quarterly revenue swung from $66.77M (Q2 2025) to $1.94M (Q3 2025), highlighting lumpiness. MYQORZO is the sole commercial product, making revenue highly concentrated.
- High short interest and profit-taking risk: Short ratio of 6.62 suggests elevated bearish positioning. After a 131% run, the stock pulled back from $88.31 high, indicating potential for further correction if momentum stalls.
CYTK Technical Analysis
Cytokinetics has been in a powerful uptrend over the past year, with the stock price surging 131.56% over the trailing 12 months, far outpacing the S&P 500's 21.46% gain. The current price of $81.37 sits at 92.1% of the 52-week range (low of $32.89, high of $88.31), indicating the stock is trading near its highs, which reflects strong momentum but also potential overextension. The 6-month price change of +30.53% and YTD change of +31.82% confirm the sustained bullish trend, though the stock has pulled back from its recent peak of $88.31, suggesting some profit-taking.
Beta
0.38
0.38x market volatility
Max Drawdown
-15.0%
Largest decline past year
52-Week Range
$33-$88
Price range past year
Annual Return
+117.8%
Cumulative gain past year
| Period | CYTK Return | S&P 500 |
|---|---|---|
| 1m | -9.6% | +2.4% |
| 3m | -0.2% | +4.6% |
| 6m | +23.1% | +11.7% |
| 1y | +117.8% | +21.4% |
| ytd | +24.3% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CYTK Fundamental Analysis
Cytokinetics is in a revenue growth phase, with Q1 2026 revenue of $19.36 million, up 11.26% year-over-year, driven by the initial sales of MYQORZO and collaboration revenue. However, revenue remains minimal compared to the company's market cap, and the growth trajectory is volatile: Q2 2025 saw a spike to $66.77 million (likely due to a one-time collaboration payment), while Q3 2025 dropped to $1.94 million, and Q4 2025 rebounded to $17.76 million. The company is still pre-profitability, with a net loss of $206.03 million in Q1 2026, and gross margin of 87.64% is high, but operating margin is deeply negative at -948.69%, reflecting heavy R&D and SG&A spending. The net margin of -1064.48% underscores the scale of losses relative to revenue, though the company's cash burn is a key concern.
Quarterly Revenue
$19355000.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
87.6%
Latest Quarter
Free Cash Flow
$-548921999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CYTK Overvalued?
Given that Cytokinetics has negative net income and EBITDA, the most appropriate valuation metric is the Price-to-Sales (PS) ratio, which stands at 86.62x trailing, while the forward PS is not directly provided but can be inferred from analyst revenue estimates. The EV/Sales ratio is even higher at 98.63x, reflecting the market's premium for the company's growth potential. Compared to the biotech industry average PS ratio (which is typically in the range of 5-10x for commercial-stage companies), Cytokinetics trades at a massive premium, indicating that investors are pricing in substantial future revenue growth from MYQORZO and the pipeline. Historically, the PS ratio has been extremely volatile, ranging from 37.86x in Q2 2022 to over 13,000x in Q3 2024, but the current level is near the lower end of recent quarters, suggesting the valuation has become more reasonable relative to its own history, though still rich in absolute terms.
PE
-9.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cytokinetics is deeply unprofitable, with a Q1 2026 net loss of $206 million and an operating margin of -948.7%. The company's TTM free cash flow is -$549 million, indicating a high cash burn rate that could necessitate dilutive financing or increased debt. With a debt-to-equity ratio of -1.95 and negative book value, the balance sheet is strained, and the company's reliance on a single product (MYQORZO) for revenue creates concentration risk. Revenue volatility is evident, with quarterly figures ranging from $1.94 million to $66.77 million, making financial planning challenging.
FAQ
The key risks are: 1) Commercial risk - MYQORZO may not achieve expected sales, leading to revenue shortfalls. 2) Financial risk - The company is burning cash (-$549M TTM FCF) and may need to dilute shareholders. 3) Valuation risk - At 86.6x sales, any disappointment could cause a severe de-rating. 4) Pipeline risk - Failure of aficamten or other candidates could hurt long-term prospects. The most severe risk is a combination of these, which could drive the stock down to the 52-week low of $32.89.
The 12-month forecast is bullish, with a base case target of $95-115 (50% probability), a bull case of $110-146 (30% probability), and a bear case of $60-83 (20% probability). The most likely scenario is the base case, where MYQORZO launch progresses steadily and the stock trades near the average analyst target of $107.80. The key assumption is that revenue growth accelerates and the company moves toward profitability. If the launch exceeds expectations, the stock could reach the high target of $146, but if it disappoints, it could fall below $83.
CYTK is overvalued based on current fundamentals, with a PS ratio of 86.6x and EV/Sales of 98.6x, far above the biotech industry average of 5-10x. However, the market is pricing in massive future revenue growth, with analysts expecting $2.32B in revenue next fiscal year. If those estimates are met, the stock could be fairly valued. Historically, the PS ratio has been even higher, so the current level is relatively more reasonable. The market expects the company to become a major player in heart failure treatment, and the valuation reflects that optimism.
CYTK is a good buy for investors with a high risk tolerance and a long-term horizon, given the strong analyst consensus (Strong Buy) and 32.5% upside to the average target of $107.80. However, the stock is extremely volatile and trades at a rich valuation of 86.6x sales, so it is not suitable for conservative investors. The biggest downside risk is a commercial launch failure, which could send the stock to the 52-week low of $32.89. If you believe in MYQORZO's potential, it could be a rewarding investment, but position sizing should be cautious.
CYTK is more suitable for long-term investment (3-5 years) given its early commercial stage and high volatility. The stock has a beta of 0.376, which is lower than the market, but its price swings are significant due to binary events like clinical trials and earnings. Short-term trading is possible but risky, as the stock can move 10%+ on news. For long-term investors, the potential for MYQORZO to become a blockbuster drug and the pipeline optionality offer substantial upside. A minimum holding period of 3 years is recommended to allow the commercial story to unfold.